Psoriatic arthritis

Researchers are testing whether apremilast helps people with early psoriatic arthritis that affects only a few joints. Participants have had symptoms for five years or less and still have joint pain and swelling despite stable treatment with NSAIDs or one conventional DMARD. The …

Researchers are testing an experimental drug called sonelokimab in adults with active psoriatic arthritis, a condition that causes painful, swollen joints along with skin psoriasis. The trial compares sonelokimab injections with placebo injections, and also includes a third group…

This study looked at the long-term safety and effectiveness of bimekizumab in adults with active psoriatic arthritis. Over 1,100 people who completed earlier studies received the drug and were monitored for side effects and disease symptoms. The goal was to see if bimekizumab rem…

This study tests whether bimekizumab works better than risankizumab for adults with active psoriatic arthritis (PsA), a condition causing joint pain and skin lesions. About 684 participants will receive one of the two drugs for 16 weeks. The main goal is to see who gets at least …

This phase 3 study tests guselkumab (Tremfya) in 453 adults with active psoriatic arthritis who did not respond to or could not tolerate a prior anti-TNF drug. Participants receive either guselkumab or a placebo injection. The main goal is to see if guselkumab reduces joint swell…

This study tracks about 450 adults with active psoriatic arthritis who are prescribed upadacitinib (RINVOQ) by their doctor. Researchers will follow participants for up to 24 months to see how well the drug controls joint and skin symptoms when used alone or with methotrexate in …

This study tested whether combining two drugs (guselkumab and golimumab) works better than one drug alone for people with active psoriatic arthritis who didn't get enough relief from previous TNF-alpha blockers. 91 adults took part. The goal was to see if the combo could help mor…

This Phase 3 trial tested bimekizumab, a drug given by injection, against a placebo in 400 adults with active psoriatic arthritis who had not responded well to TNF-alpha inhibitors. The study aimed to see if bimekizumab could reduce joint pain and swelling and improve daily funct…

This study tested a drug called bimekizumab in 852 adults with active psoriatic arthritis, a condition causing joint pain, swelling, and skin patches. Participants received either bimekizumab, a placebo, or an existing treatment (adalimumab). The main goal was to see if bimekizum…

This phase 3 trial tests whether risankizumab, an injectable biologic, can reduce joint pain and swelling in adults with moderately to severely active psoriatic arthritis who have not responded to or cannot tolerate other biologic treatments. Participants receive either risankizu…

This study investigates whether changing diet can reduce disease activity in people with psoriatic arthritis. Participants are randomly assigned to one of two diets: one focusing on which foods are eaten, and another limiting daily calorie intake. The trial lasts 24 weeks and inc…

This Phase 3 study tested guselkumab, a drug given by injection, in 741 adults with active psoriatic arthritis. The goal was to see if it reduces joint pain and swelling. Participants received either guselkumab or a placebo. The main measure was a 20% improvement in arthritis sym…

This study tested whether adding a weight-loss drug (tirzepatide) to a standard arthritis drug (ixekizumab) helps people with psoriatic arthritis who are overweight or obese. 279 adults with active psoriatic arthritis and a BMI of 27 or higher took part. The goal was to see if th…

This study tracked over 2,300 adults in Korea who were prescribed Skyrizi (risankizumab) for moderate to severe plaque psoriasis or psoriatic arthritis. Researchers monitored side effects and symptom changes for 52 weeks during routine doctor visits. The goal was to confirm the d…

This study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see how well bimekizumab cleared skin lesions after 16 weeks. Results showed s…

This phase 3 study tested bimekizumab, a drug given by injection, against a placebo in 435 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% skin clearing after 16 weeks. The trial also looked at complete clearing and …

This study tested whether people with rheumatoid arthritis, psoriatic arthritis, or spine arthritis could safely switch from receiving infliximab through an IV infusion at a clinic to giving themselves a simple shot under the skin at home. 22 adults who were already stable on IV …

This study looked at how safe and effective upadacitinib is for Korean patients with rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis, or psoriatic arthritis. Over 2,300 adults took the drug as prescribed by their doctor and were followed for about 28 weeks. Resear…

This study looked at 70 people with psoriatic arthritis to compare two drug types: upadacitinib and IL-17 inhibitors. Researchers tracked joint and skin symptoms over 24 weeks in routine care. The goal is to see which works better in real life, helping doctors personalize treatme…

This phase 3 trial tested a single injection of tildrakizumab against placebo in 508 adults with active psoriatic arthritis who had previously used anti-TNF drugs. The main goal was to see if more people achieved at least a 20% improvement in joint symptoms. The study is now comp…

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis who had initially improved on the standard dose of Remicade but later lost that benefit. The goal was to see if the increased dose could again reduce skin symptoms. Participant…

This study tested whether adding GOLimumab to methotrexate works better than methotrexate alone for people with very early psoriatic arthritis (PsA). 84 adults with active PsA diagnosed within the last 2 years took part. The main goal was to see if the combination improved diseas…

This completed trial tested whether starting stronger medications early helps people with moderate to severe psoriatic arthritis more than the usual step-up approach. 192 adults were randomly assigned to standard care, early combination disease-modifying drugs, or early TNF inhib…

This pilot study tested whether adding metformin to standard care can slow the buildup of plaque in the carotid arteries of people with psoriatic arthritis (PsA) who do not have diabetes. Twenty-four participants with PsA and existing carotid plaque were randomly assigned to take…

This study tested two biologic drugs, secukinumab and ustekinumab, in 119 adults with active psoriatic arthritis who had not responded to or could not tolerate TNFα-inhibitor treatment. The main goal was to see which drug better improved physical function over 28 weeks. Researche…

This study looked at how well the drug tofacitinib works for people with psoriatic arthritis in everyday medical practice. Over 12 months, researchers tracked 116 adults to see if the drug reduced disease activity and improved quality of life. The goal was to understand real-worl…

This study tested an oral drug called upadacitinib (RINVOQ) against a placebo and an injected drug (adalimumab/Humira) in 1705 people with active psoriatic arthritis who had not responded well to standard non-biologic treatments. The goal was to see if upadacitinib reduces joint …

This phase 3 study tested upadacitinib, an oral anti-inflammatory drug, in 642 adults with active psoriatic arthritis who had not responded well to at least one biologic treatment. Participants received either 15 mg or 30 mg of upadacitinib daily or a placebo. The main goal was t…

This completed study observed over 1,000 people with psoriasis who were prescribed OTEZLA (apremilast) for the first time. Researchers tracked side effects, symptom improvement, and quality of life over several years. The goal was to see how well the drug works in real-world sett…

This study followed 76 adults who received a total shoulder replacement using the MIRAI modular prosthesis. Researchers measured how well the shoulder functioned and how stable the implant was over five years. The goal was to see if the implant helps patients move better and last…

This study followed 526 adults with active psoriatic arthritis who were already prescribed apremilast (Otezla) by their doctors. Researchers observed them for up to 100 weeks to see how well the drug controlled their symptoms in everyday practice. The goal was to gather long-term…

This trial tests a new 24-week program called COMFI that combines a cognitive behavioral approach with physical activity to help people with inflammatory arthritis manage fatigue. Participants attend group sessions, an optional individual session, and a booster session, and they …

This study tests whether blood flow restriction training (BFRT) — using pressure cuffs during low-load exercise — can help people with rheumatoid or psoriatic arthritis build muscle with less joint strain than conventional strength training. Adults with these conditions will be r…

This study tested a self-guided online program for people with psoriasis. 348 adults were split into two groups: one got the app plus their regular treatment, the other got regular treatment alone. The main goal was to see if the app improved quality of life over 12 months.

This study tested whether a food formula containing medium-chain triglycerides (MCTs) and vegetable fibers could improve quality of life in 72 adults with psoriatic arthritis and low disease activity. Participants took the formula for 3 months while continuing their usual medicat…

This study looked at whether intermittent fasting (eating only during certain hours) can reduce disease severity and improve quality of life for people with psoriasis and psoriatic arthritis. Sixty overweight adults were randomly assigned to either follow an intermittent fasting …

This study involved 324 adults with conditions like Crohn's disease, arthritis, or psoriasis who switched from a standard to a higher-concentration form of adalimumab (AVT-02). Researchers measured injection site pain and how well patients stuck with their treatment over 180 days…

This study tested whether two structured telemedicine visits, added between regular doctor appointments, could help people with psoriatic arthritis improve their quality of life and reduce disease impact. 101 adults with active symptoms took part. The visits focused on lifestyle …

This study tested whether an 8-week ketogenic or Mediterranean diet could reduce inflammation in 26 adults with obesity, psoriasis, and psoriatic arthritis. Participants followed one of the two diets, and researchers measured skin severity (PASI score) and joint activity (DAPSA s…

This study tested a 12-week online program called Immune Strength for people with psoriasis or psoriatic arthritis. The program provided tips on stress, sleep, nutrition, and exercise, plus one-on-one email coaching from a wellness professional. Researchers wanted to see if this …

This study is looking at how nutrition affects disease activity in people with rheumatic diseases like rheumatoid arthritis, lupus, and psoriatic arthritis. Researchers will measure the nutritional status of 460 participants using several different tools and compare it to how act…

This study follows people newly diagnosed with psoriatic arthritis (PsA) to see how a 'treat to target' approach works in everyday clinics. Participants receive standard care, often starting with methotrexate, and their disease activity is tracked over time. The goal is to unders…

This study looked at whether healthcare professionals in Saudi Arabia are aware of and follow safety measures for the drug leflunomide, used for rheumatoid and psoriatic arthritis. Researchers surveyed 302 doctors and pharmacists to see if they received and read safety materials,…

This completed study looked at how the COVID-19 pandemic and social distancing impacted the mental health of 259 adults with chronic inflammatory rheumatism (like rheumatoid arthritis or ankylosing spondylitis). Researchers used questionnaires to measure stress, depression, anxie…

This completed study investigated whether air pollution affects flare-ups in people with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis. Researchers followed 86 patients for 6 months, asking them to complete weekly questionnaires about their symptoms. They a…

This completed study looked at nearly 7,000 adults with inflammatory joint diseases like rheumatoid arthritis and psoriatic arthritis. Researchers compared two versions of a standard health survey (EQ-5D-3L and EQ-5D-5L) to see which one better measures health and quality of life…

This study aimed to create and test a decision aid for people with psoriasis or psoriatic arthritis who are starting or switching treatments. Researchers worked with 37 patients and their doctors to design a tool that supports shared decision-making. The goal was to help patients…

This study looked at fatigue in 33 adults with psoriatic arthritis or psoriasis. Researchers used questionnaires to measure tiredness and see how it relates to disease severity and treatments. The goal was to better understand fatigue and its impact on quality of life.

This study tested whether a non-invasive ultrasound device can reduce inflammation in people with inflammatory arthritis (psoriatic arthritis, rheumatoid arthritis, or ankylosing spondylitis). Sixteen participants received four sessions of focused ultrasound or a sham (placebo) t…

This completed study surveyed 229 people with chronic inflammatory rheumatism (like rheumatoid arthritis) and their doctors to find out what makes it hard to follow care recommendations after a hospital visit. The goal was to identify barriers to good outpatient management. No tr…

This study looked at 70 people with spondyloarthritis, a type of inflammatory arthritis affecting the spine and joints. Researchers measured immune markers in the blood to see if they could predict how the disease would progress or how well patients would respond to treatment. Th…

This study looked at real-world data from over 140,000 people in Sweden with rheumatoid arthritis or psoriatic arthritis. Researchers tracked how many people developed different types of cancer while taking abatacept or other arthritis drugs. The goal was to better understand the…

This completed study looked at the safety of the arthritis drug abatacept in over 38,000 people with rheumatoid or psoriatic arthritis in Denmark. Researchers used a national health registry to track rates of cancers and other side effects. The goal was to better understand the d…

This study looked at how a special exercise approach called BETY affects people with rheumatic diseases (like arthritis) who have chronic pain. Researchers reviewed past records of 300 participants to see if BETY improved their physical function, mood, and quality of life compare…

This completed study followed 127 adults with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis who were already taking or starting secukinumab. Researchers observed them for two years to see how long the…

This completed study examined why people with rheumatoid arthritis (RA) and lupus have a higher risk of heart attacks. Researchers collected blood samples from 176 participants and tested how statins and adenosine A2A receptor agonists affected cholesterol balance in cells. The g…

This study checked if newer psoriasis drugs (IL17/23 inhibitors) also improve artery stiffness, a sign of heart disease. Researchers followed 66 people with moderate-to-severe psoriasis for a year, measuring pulse wave velocity (PWV) and other markers. The goal was to see if thes…